ValiRx PLC

As of December 31, 2025, ValiRx PLC carries a market capitalization of 248.81M, placing it among publicly traded companies globally. Its enterprise value stands at 123.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ValiRx PLC's next confirmed earnings release is scheduled for June 9, 2027.

As of December 31, 2025, ValiRx PLC has 742.72M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, ValiRx PLC maintains a current ratio of 4.62, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, ValiRx PLC's stock has declined approximately 73.33% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.23.

As of December 31, 2025, ValiRx PLC holds 79.16M in cash and equivalents against 139,500.00 in total debt, resulting in a net debt position of -79.02M. Total book value stands at 285.50M, with working capital of 85.09M providing operational flexibility.

ValiRx PLC's most recent stock split took place on April 6, 2020 with a 125:1 split ratio.